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A B S T R A C T
Purpose
Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited.
Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced
gastric or gastroesophageal junction cancers. We assessed the safety and efﬁcacy of nivolumab and
nivolumab plus ipilimumab in Western patients with chemotherapy-refractory esophagogastric cancers.
Patients and Methods
Patients with locally advanced or metastatic chemotherapy–refractory gastric, esophageal, or
gastroesophageal junction cancer from centers in the United States and Europe received nivolumab
or nivolumab plus ipilimumab. The primary end point was objective response rate. The association of
tumor programmed death-ligand 1 status with response and survival was also evaluated.
Results
Of 160 treated patients (59 with nivolumab 3 mg/kg, 49 with nivolumab 1 mg/kg plus ipilimumab
3 mg/kg, 52 with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg), 79% had received two or more prior
therapies. At the data cutoff, investigator-assessed objective response rates were 12% (95% CI,
5% to 23%), 24% (95% CI, 13% to 39%), and 8% (95% CI, 2% to 19%) in the three groups,
respectively. Responses were observed regardless of tumor programmed death-ligand 1 status.
With a median follow-up of 28, 24, and 22 months across the three groups, 12-month progression-
free survival rates were 8%, 17%, and 10%, respectively; 12-month OS rates were 39%, 35%, and
24%, respectively. Treatment-related grade 3/4 adverse events were reported in 17%, 47%, and
27% of patients in the three groups, respectively.
Conclusion
Nivolumab and nivolumab plus ipilimumab demonstrated clinically meaningful antitumor activity,
durable responses, encouraging long-term OS, and a manageable safety proﬁle in patients with
chemotherapy-refractory esophagogastric cancer. Phase III studies evaluating nivolumab or
nivolumab plus ipilimumab in earlier lines of therapy for esophagogastric cancers are underway.
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INTRODUCTION
Metastatic esophagogastric cancer is a global
health burden and a substantial cause of cancer-
related mortality worldwide.1,2 For patients with
disease progression receiving second-line therapy,
the prognosis remains poor; thus, effective treat-
ment options are urgently needed.3,4 The patho-
genesis of esophagogastric adenocarcinoma has
been linked to chronic inﬂammation, DNA
damage that results in highmicrosatellite instability
(MSI), high mutational burden, and overexpression
of immune checkpoint proteins.5-8 These ﬁndings
suggest that immune checkpoint inhibition is a vi-
able therapeutic strategy for patients with esoph-
agogastric cancer. The anti–programmed death-1
(PD-1) monoclonal antibodies nivolumab and
pembrolizumab have demonstrated promising ac-
tivity in early clinical trials that included patients
with esophagogastric cancers.9-11
On the basis of superior survival demon-
strated in the phase III, randomized, placebo-
controlled ATTRACTION-2 trial,12 nivolumab
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was approved in Japan for the treatment of patients with
chemotherapy-refractory gastric and gastroesophageal junction (GEJ)
cancers regardless of programmed death-ligand 1 (PD-L1) status. Also,
in the United States, pembrolizumab was approved for the treatment
of patients with chemotherapy-refractory PD-L1–positive gastric/GEJ
cancer on the basis of the promising clinical activity observed in the
KEYNOTE-059 trial.10 Dual PD-1/cytotoxic T-lymphocyte–associated
antigen 4 blockadewith nivolumab plus ipilimumab has demonstrated
synergistic activity in preclinical models13,14 and has led to enhanced
response rates in patients with metastatic melanoma, small-cell lung
cancer, and DNA mismatch repair–deﬁcient/MSI–high (MSI-H)
metastatic colorectal cancer.15-17 We present the safety, efﬁcacy,
long-term survival, and biomarker analyses of nivolumab and
nivolumab plus ipilimumab in Western patients with chemotherapy-
refractory locally advanced or metastatic esophagogastric cancer from
the multicenter, phase I/II CheckMate-032 trial.
PATIENTS AND METHODS
Study Design and Treatment
CheckMate-032 is an ongoing, open-label, two-stage, multicohort,
phase I/II trial. The esophagogastric cohort of CheckMate-032 enrolled
patients at 18 centers in the United States and ﬁve European countries. The
study protocol and all amendments were approved by local institutional
review boards, and the protocol was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice Guidelines, as deﬁned by
the International Conference on Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use. All patients provided written informed
consent before enrollment. Patients were randomly assigned, when multiple
treatment groups were open, to one of the following: nivolumab 3 mg/kg
(NIVO3) intravenously every 2 weeks; nivolumab 1 mg/kg plus ipilimumab
3mg/kg (NIVO1 + IPI3) every 3 weeks for four cycles; or nivolumab 3mg/kg
plus ipilimumab 1 mg/kg (NIVO3 + IPI1) every 3 weeks for four cycles. All
combination regimens were followed by NIVO3 every 2 weeks until disease
progression or unacceptable adverse event (AE). Treatment beyond disease
progression was permitted in patients with clinical beneﬁt on the basis of
investigator assessment. Patients who were assigned to the NIVO3 group and
experienced disease progression could cross over to a combination group.
Dose reductions or modiﬁcations were not permitted with nivolumab or
ipilimumab. Dose interruption was allowed. The criteria for treatment dis-
continuation and interruption are summarized in the Appendix (online only).
Patients
Key eligibility criteria for the esophagogastric cancer cohort included
diagnosis of locally advanced or metastatic gastric, esophageal, or GEJ
adenocarcinoma with disease progression while taking or intolerance of at
least one chemotherapy regimen; measurable disease as assessed by Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) version 1.118;
Eastern Cooperative Oncology Group performance status of 0 or 1; and
adequate organ function. Patients with human epidermal growth factor
receptor 2–positive tumors were eligible if they had received previous
treatment with trastuzumab. Key exclusion criteria included suspected
autoimmune disease; hepatitis B virus or human immunodeﬁciency virus
infection; conditions requiring corticosteroids or other immunosup-
pressive medications; and previous immune checkpoint inhibitor therapy.
Study Assessments
The primary end point was objective response rate (ORR), deﬁned as
the best response of complete response or partial response divided by the
number of treated patients, per RECIST version 1.1.18 ORR was assessed by
investigator and by blinded independent central review (BICR). Secondary
end points included overall survival (OS), progression-free survival (PFS),
duration of response (DOR), and safety. Tumor response was assessed
using imaging every 6 weeks for 24 weeks, then every 12 weeks until disease
progression or treatment discontinuation. Survival was monitored con-
tinuously while patients were receiving treatment and every 3 months after
treatment discontinuation. Clinical activity was also assessed by tumor PD-
L1 andMSI status. AEs were assessed and graded using the National Cancer
Institute Common Terminology Criteria for Adverse Events version 4.0.19
Tumor PD-L1 expression was assessed centrally using a validated,
automated immunohistochemistry assay (Dako North America, Carpin-
teria, CA) of archival samples obtained before enrollment or new biopsy
specimens. Samples with $ 100 evaluable tumor cells and $ 1% PD-L1
staining of tumor cell membranes were considered PD-L1–positive. MSI
status was established retrospectively on available tumor/normal paired
samples using a polymerase chain reaction–based assay on the basis of the
Table 1. Baseline Patient and Disease Characteristics
Characteristic
NIVO3
(n = 59)
NIVO1 + IPI3
(n = 49)
NIVO3 + IPI1
(n = 52)
Median age, years (range) 60 (29-80) 53 (27-77) 58 (19-81)
Age $ 65 years 17 (29) 10 (20) 17 (33)
Male sex 45 (76) 34 (69) 45 (87)
Race
White 56 (95) 46 (94) 50 (96)
Black/Asian/other 3 (5) 3 (6) 2 (4)
ECOG PS
0 29 (49) 27 (55) 18 (35)
1 30 (51) 22 (45) 34 (65)
Primary tumor location
Gastric 19 (32) 22 (45) 18 (35)
Esophageal 9 (15) 8 (16) 9 (17)
GEJ 31 (53) 19 (39) 25 (48)
Site of metastases
Lymph node 39 (66) 29 (59) 32 (62)
Peritoneum 13 (22) 8 (16) 9 (17)
Liver 31 (53) 27 (55) 26 (50)
Lung 20 (34) 12 (24) 17 (33)
Prior regimens
0 0 1 (2) 0
1 10 (17) 6 (12) 16 (31)
2 20 (34) 19 (39) 16 (31)
3 19 (32) 11 (22) 13 (25)
. 3 10 (17) 12 (24) 7 (13)
Prior therapies
Fluoropyrimidine 59 (100) 47 (96) 50 (96)
Platinum 57 (97) 45 (92) 49 (94)
Taxane 38 (64) 33 (67) 32 (62)
Anti-HER2 14 (24) 12 (24) 16 (31)
Prior radiotherapy 24 (41) 13 (27) 26 (50)
HER2
Positive 8 (14) 5 (10) 9 (17)
Negative 30 (51) 22 (45) 25 (48)
Unknown 21 (36) 22 (45) 18 (35)
MSI status (n = 25) (n = 23) (n = 24)
MSI-H 7 (28)* 2 (9)* 2 (8)*
Non–MSI-H 18 (72)* 21 (91)* 22 (92)*
Not evaluable/missing 34 (58) 26 (53) 28 (54)
PD-L1 expression (n = 42) (n = 42) (n = 43)
$ 1 16 (38)* 10 (24)* 13 (30)*
, 1 26 (62)* 32 (76)* 30 (70)*
Not evaluable/missing 17 (29) 7 (14) 9 (17)
NOTE. Data presented as No. (%) unless otherwise indicated.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance
status; GEJ, gastroesophageal junction; HER2, human epidermal growth factor
receptor 2; IPI1, ipilimumab 1 mg/kg; IPI3, ipilimumab 3 mg/kg; MSI, micro-
satellite instability; MSI-H, microsatellite instability–high; NIVO1, nivolumab
1 mg/kg; NIVO3, nivolumab 3 mg/kg; PD-L1, programmed death-ligand 1.
*Percentage of evaluable patients.
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Bethesda panel of mononucleotide and dinucleotide markers.20 Samples
positive for two or more markers of instability were classiﬁed as MSI-H.
Statistical Analyses
Each treatment group was evaluated separately for the primary end
point of ORR using a modiﬁed Simon two-stage study design,21 with 80%
power to reject the null hypothesis of ORR # 10% (insufﬁcient drug ac-
tivity), assuming that the true ORRwas 25%, with a one-sideda of .05. Thus,
the trial was not designed or powered for a formal comparison of the
treatment groups. In thismulticohort trial, anORR of 25%was considered to
be of clinical interest across tumor types and was not speciﬁcally selected
based on the esophagogastric cancer cohort. In addition, the tests did not
adjust for multiplicity across the different tumor type cohorts in CheckMate-
032. In the ﬁrst stage, 18 patients were enrolled per group. If at least two
responses were observed, accrual was expanded in the second stage to 22
additional patients, for a total of 40 patients per group. The treatment was
considered of clinical interest if at least 20% of patients (eight of 40) ex-
perienced an objective response. On the basis of the results of phase I studies
in other solid tumors,22-24 it was hypothesized thatNIVO3 + IPI1 would have
similar efﬁcacy and improved safety; thus, the NIVO3 + IPI1 group was not
based on a two-stage design and was started once the NIVO1 + IPI3 group
proceeded to the second stage. The protocol permitted further expansion of
treatment groups on the basis of the clinical activity.
The BICR assessment of the NIVO3 group was based on the March
2016 data cutoff. All other efﬁcacy and safety assessments for the treatment
groups were based on the November 2016 data cutoff. ORR was sum-
marized by a binomial proportion and corresponding two-sided 95% exact
CIs using the Clopper-Pearson method. DOR, PFS, and OS were sum-
marized using medians and time point–speciﬁc survival rates by Kaplan-
Meier and two-sided 95%CIs. Descriptive statistics were used to characterize
patient characteristics and safety. Statistical analyses were performed using
SAS software (version 9.2; SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Patients were enrolled and treated from November 19, 2013,
through June 3, 2015. At the time of the data cutoff, 160 patients
received NIVO3 (n = 59), NIVO1 + IPI3 (n = 49), or NIVO3 + IPI1
(n = 52). Of the 160 patients, 79% had received two or more prior
therapies; 49%, 47%, and 38% of patients across the three groups had
received three or more prior lines of therapy, respectively (Table 1).
Tumor samples were evaluable for PD-L1 and MSI status in 79% and
45% of patients, respectively. The NIVO3 group had higher per-
centages of patients with PD-L1–positive tumors (38%) and MSI-H
status (28%) than either of the combination groups (NIVO1 + IPI3:
PD-L1–positive, 24%, andMSI-H, 9%;NIVO3+ IPI1: PD-L1–positive,
30%, and MSI-H, 8%). Median duration of follow-up (potential time
on study from ﬁrst dose to database lock) in the three groups was
28 months (range, 17 to 35 months) in the NIVO3 group, 24 months
(range, 21 to 33 months) in the NIVO1 + IPI3 group, and 22 months
(range, 19 to 25 months) in the NIVO3 + IPI1 group; most patients in
each treatment group (NIVO3, 97%; NIVO1 + IPI3, 88%; NIVO3 +
IPI1, 94%) had discontinued treatment at the time of the data cutoff.
The most common reason for discontinuation of treatment across all
groups was disease progression (Appendix Fig A1, online only). After
discontinuation of study therapy, approximately one third of patients in
each treatment group (36% overall) went on to receive subsequent
anticancer therapy, consisting of chemotherapy inmost patients (84%).
Efficacy
Investigator-assessed ORR was 12% with NIVO3, 24% with
NIVO1 + IPI3, and 8%with NIVO3 + IPI1 (Table 2). Median DOR
was 7.1 months (95% CI, 3.0 to 13.2 months) in the NIVO3 group,
7.9 months (95% CI, 2.8 months to not estimable) in the NIVO1 +
IPI3 group, and not yet reached (95% CI, 2.5 months to not
estimable) in the NIVO3 + IPI1 group (Figs 1A-1C). Responses
were observed with NIVO3, NIVO1 + IPI3, and NIVO3 + IPI1
regardless of tumor PD-L1 expression (Table 3; BICR in Appendix
Table A1, online only). Objective responses were observed in both
patients with MSI-H and those with non–MSI-H tumors (Table 3;
Appendix Fig A2, online only). Additional efﬁcacy outcomes per
BICR are presented in Appendix Figure A3 (online only).
Among evaluable patients, 29%, 45%, and 27% of patients in the
NIVO3, NIVO1 + IPI3, and NIVO3 + IPI1 groups, respectively, had
a reduction in tumor burden from baseline per investigator assessment
(Fig 1D; BICR in Appendix Fig A4, online only). The median time to
response ranged from 1.6 to 2.7 months (Table 2). Disease control
(complete response, partial response, and stable disease) was achieved
by 32% to 41%of patients (Table 2). Stable disease for at least 12 weeks
was achieved by 67%, 63%, and 67% of patients with stable disease in
the NIVO3, NIVO1 + IPI3, and NIVO3 + IPI1 groups, respectively. At
the time of the data cutoff,ﬁve patients in theNIVO1+ IPI3 group and
two patients in the NIVO3 + IPI1 group had ongoing responses
by investigator assessment (Appendix Fig A2, online only).
Median PFS by investigator assessment was 1.4 months (95%
CI, 1.2 to 1.5 months) in the NIVO3 group, 1.4 months (95%CI, 1.2
Table 2. ORR, DCR, and DOR per Investigator Assessment and BICR
Variable
NIVO3 (n = 59) NIVO1 + IPI3 (n = 49) NIVO3 + IPI1 (n = 52)
Investigator BICR Investigator BICR Investigator BICR
ORR, No. (%; 95% CI) 7 (12; 5 to 23) 4 (7; 2 to 17) 12 (24; 13 to 39) 10 (20; 10 to 34) 4 (8; 2 to 19) 2 (4; 1 to 13)
Complete response 1 (2) 0 1 (2) 1 (2) 0 1 (2)
Partial response 6 (10) 4 (7) 11 (22) 9 (18) 4 (8) 1 (2)
Stable disease 12 (20) 18 (31) 8 (16) 13 (27) 15 (29) 17 (33)
Progressive disease 34 (58) 26 (44) 23 (47) 18 (37) 24 (46) 25 (48)
Unable to determine 6 (10) 11 (19) 6 (12) 8 (16) 9 (17) 8 (15)
DCR, No. (%)* 19 (32) 22 (37) 20 (41) 23 (47) 19 (37) 19 (37)
Median TTR, months (range) 1.6 (1.2 to 4.0) 1.4 (1.2 to 2.1) 2.7 (1.2 to 14.5) 2.6 (1.1 to 4.2) 2.6 (1.3 to 2.8) 2.0 (1.2 to 2.7)
Median DOR, months (95% CI) 7.1 (3.0 to 13.2) 14.1 (2.8 to 14.1) 7.9 (2.8 to NE) NR (2.7 to NE) NR (2.5 to NE) NR (NE to NE)
Abbreviations: BICR, blinded independent central review; DCR, disease control rate; DOR, duration of response; IPI1, ipilimumab 1 mg/kg; IPI3, ipilimumab 3 mg/kg;
NE, not estimable; NIVO1, nivolumab 1 mg/kg; NIVO3, nivolumab 3 mg/kg; NR, not reached; ORR, objective response rate; TTR, time to response.
*Patients with a best objective response of complete response, partial response, or stable disease.
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Fig 1. Changes in tumor burden per in-
vestigator assessment in individual patients.
Percentage change from baseline in target le-
sions over time with (A) nivolumab 3 mg/kg
(NIVO3), (B) nivolumab 1 mg/kg plus ipilimumab
3 mg/kg (NIVO1 + IPI3), (C) NIVO3 plus ipili-
mumab 1 mg/kg (NIVO3 + IPI1), and (D) the
reduction in maximum percentage change from
baseline in size of tumors by treatment group.
Patients with 0% best reduction in target lesion
are not shown on the plot (NIVO3, n = 2; NIVO1 +
IPI3, n = 1; NIVO3 + IPI1, n = 1). Triangle in-
dicates investigator-assessed conﬁrmed com-
plete or partial response, square indicates
percent change truncated at 100%, closed circle
represents patients off treatment, and cross
represents ﬁrst occurrence of a new lesion. (*)
Indicates patients with a conﬁrmed response
(complete or partial response), and the bars
representing patients with a percentage change
in tumor burden that exceeds 100% have been
truncated.
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to 3.8 months) in the NIVO1 + IPI3 group, and 1.6 months (95%
CI, 1.4 to 2.6 months) in the NIVO3 + IPI1 group (Fig 2A; BICR in
Appendix Fig A5, online only). The 12-month PFS rate was 8%
(95% CI, 3% to 17%) in the NIVO3 group, 17% (95% CI, 8% to
29%) in the NIVO1 + IPI3 group, and 10% (95%CI, 3% to 20%) in
the NIVO3 + IPI1 group. The median OS was 6.2 months (95% CI,
3.4 to 12.4months) in the NIVO3 group, 6.9months (95%CI, 3.7 to
11.5 months) in the NIVO1 + IPI3 group, and 4.8 months (95% CI,
3.0 to 8.4 months) in the NIVO3 + IPI1 group (Fig 2B). The
12-month OS rate was 39% (95% CI, 26% to 52%) in the NIVO3
group, 35% (95% CI, 22% to 49%) in the NIVO1 + IPI3 group, and
24% (95% CI, 13% to 37%) in the NIVO3 + IPI1 group. The
12-month OS rates by PD-L1 and MSI status are listed in Table 3.
Safety
Treatment-related AEs (TRAEs) occurred in 69% of patients
in the NIVO3 group, 84% of patients in the NIVO1 + IPI3 group, and
75% of patients in the NIVO3 + IPI1 group. The most common
($ 15%) TRAEs across all treatment groups included fatigue, pru-
ritus, rash, diarrhea, decreased appetite, and increased ALT and AST
levels (Table 4). Grade 3/4 TRAEs were reported in 17%, 47%, and
27% of patients receiving NIVO3, NIVO1 + IPI3, and NIVO3 + IPI1,
respectively. TRAEs resulted in treatment discontinuation in 3% of
patients in the NIVO3 group, 20% of patients in the NIVO1 + IPI3
group, and 13% of patients in the NIVO3 + IPI1 group. Serious
TRAEs occurred in 10%, 43%, and 25% of patients receiving NIVO3,
NIVO1 + IPI3, and NIVO3 + IPI1, respectively. One death due to
tumor lysis syndrome, deemed by the investigator to be possibly
treatment related, occurred in the NIVO3 + IPI1 group.
DISCUSSION
Results of the CheckMate-032 study reported here demonstrate for
the ﬁrst time that nivolumab and nivolumab plus ipilimumab
provide clinically meaningful and durable antitumor activity with
a manageable safety proﬁle in heavily pretreated Western patients
with chemotherapy-refractory esophagogastric cancer. Notably,
the clinical activity with nivolumab monotherapy in our study was
consistent with that reported with nivolumab in Asian patients in
the ATTRACTION-2 study.12 Taken together with other reports on
anti–PD-1 therapy,9,25 these ﬁndings suggest that despite the
morphologic and molecular heterogeneity of esophagogastric
cancer, immune checkpoint blockade provides a consistent ther-
apeutic beneﬁt across Asian and Western patients.
Considering the aggressive biology of metastatic esophagogastric
cancer, combined immune checkpoint blockade may further improve
the efﬁcacy of single-agent anti–PD-1 therapy by avoiding tumor
immune escape through synergistic T-cell antitumor activity.13,14
NIVO1 + IPI3 has demonstrated clinical activity and a manageable
safety proﬁle in other solid tumors15,16 and is Food and Drug Ad-
ministration approved for the treatment of melanoma.26 The results
with NIVO1 + IPI3 therapy reported here demonstrate an ORR of
24%; however, despite the numerically higher ORR achieved in pa-
tients receiving NIVO1 + IPI3 than in those receiving NIVO3, median
OS was similar between these groups. One explanation for this ob-
servation may be the higher proportion of patients with MSI-H and
PD-L1–positive tumors in the NIVO3 group. The enhanced clinical
beneﬁt observed with NIVO1 + IPI3 was accompanied by a numer-
ically higher incidence of grade 3/4 AEs than observed with NIVO3.
These events were primarily diarrhea and elevated liver enzyme levels
and were manageable using protocol-speciﬁed AE management al-
gorithms. In contrast, NIVO3 + IPI1 had comparable clinical activity
and a numerically higher overall rate of AEs compared with NIVO3.
These ﬁndings suggest that the lower ipilimumab dose may not have
been sufﬁcient to enhance anti–PD-1–mediated immune responses in
this patient population. On the basis of the numerically higher overall
response and landmark OS rates in the NIVO1 + IPI3 arm, this
combination was considered more likely to offer clinical beneﬁt rel-
ative to currently available treatment regimens for ﬁrst-line metastatic
esophagogastric cancer and was selected for further evaluation in the
phase III CheckMate-649 study (NCT02872116).
To identify potential biomarkers of response to nivolumab and
nivolumab plus ipilimumab, treatment response and outcomes were
explored by tumor PD-L1 and MSI status. Responses were observed
regardless of tumor PD-L1 status across the treatment groups. Al-
though the ORR seemed numerically higher in patients with PD-
L1–positive versus PD-L1–negative tumors, the sample size was small,
with overlapping CIs between these subgroups. Of note, tumor PD-L1
status was not predictive of survival with nivolumab in patients with
gastric/GEJ cancer in the phase III ATTRACTION-2 trial.12
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Fig 1. (Continued).
jco.org © 2018 by American Society of Clinical Oncology 5
Nivolumab and Nivolumab Plus Ipilimumab in Esophagogastric Cancer
Downloaded from ascopubs.org by University of Glasgow Library on August 17, 2018 from 130.209.115.202
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Ta
bl
e
3.
In
ve
st
ig
at
or
-A
ss
es
se
d
R
es
po
ns
e
an
d
O
S
by
P
D
-L
1
an
d
M
S
I
S
ta
tu
s
R
es
po
ns
e/
O
S
N
IV
O
3
(n
=
59
)
N
IV
O
1
+
IP
I3
(n
=
49
)
N
IV
O
3
+
IP
I1
(n
=
52
)
P
D
-L
1+
(n
=
16
)
P
D
-L
12
(n
=
26
)
M
S
I-H
(n
=
7)
N
on
–
M
S
I-H
(n
=
18
)
P
D
-L
1+
(n
=
10
)
P
D
-L
12
(n
=
32
)
M
S
I-H
(n
=
2)
N
on
–
M
S
I-H
(n
=
21
)
P
D
-L
1+
(n
=
13
)
P
D
-L
12
(n
=
30
)
M
S
I-H
(n
=
2)
N
on
–
M
S
I-H
(n
=
22
)
O
R
R
,
N
o.
(%
;
95
%
C
I)
3
(1
9;
4
to
46
)
3
(1
2;
2
to
30
)
2
(2
9;
4
to
71
)*
2
(1
1;
1
to
35
)†
4
(4
0;
12
to
74
)
7
(2
2;
9
to
40
)
1
(5
0;
1
to
99
)*
4
(1
9;
5
to
42
)†
3
(2
3;
5
to
54
)
0
(0
;
0
to
12
)
1
(5
0;
1
to
99
)*
1
(5
;
0.
1
to
23
.0
)†
D
C
R
,
N
o.
(%
)‡
5
(3
1)
11
(4
2)
5
(7
1)
5
(2
8)
5
(5
0)
13
(4
1)
1
(5
0)
9
(4
3)
5
(3
8)
10
(3
3)
1
(5
0)
8
(3
6)
O
S
ra
te
,
m
on
th
s,
%
(9
5%
C
I)
12
34
(1
2
to
57
)
45
(2
5
to
63
)
57
(1
7
to
84
)
33
(1
4
to
55
)
50
(1
8
to
75
)
32
(1
6
to
48
)
50
(1
to
91
)
32
(1
6
to
48
)
23
(6
to
47
)
25
(1
1
to
42
)
50
(1
to
91
)
23
(8
to
43
)
18
13
(2
to
35
)
28
(1
3
to
47
)
29
(4
to
61
)
17
(4
to
37
)
50
(1
8
to
75
)
24
(1
0
to
40
)
50
(1
to
91
)
30
(1
2
to
51
)
15
(3
to
39
)
8
(2
to
23
)
50
(1
to
91
)
6
(0
to
23
)
A
bb
re
vi
at
io
ns
:D
C
R
,d
is
ea
se
co
nt
ro
lr
at
e;
D
O
R
,d
ur
at
io
n
of
re
sp
on
se
;I
P
I1
,i
pi
lim
um
ab
1
m
g/
kg
;I
P
I3
,i
pi
lim
um
ab
3
m
g/
kg
;M
S
I-H
,m
ic
ro
sa
te
lli
te
in
st
ab
ili
ty
–
hi
gh
;N
IV
O
1,
ni
vo
lu
m
ab
1
m
g/
kg
;N
IV
O
3,
ni
vo
lu
m
ab
3
m
g/
kg
;
O
R
R
,
ob
je
ct
iv
e
re
sp
on
se
ra
te
;
O
S
,
ov
er
al
ls
ur
vi
va
l;
P
D
-L
1,
pr
og
ra
m
m
ed
de
at
h-
lig
an
d
1;
P
D
-L
12
,
pr
og
ra
m
m
ed
de
at
h-
lig
an
d
1–
ne
ga
tiv
e;
P
D
-L
1+
,
pr
og
ra
m
m
ed
de
at
h-
lig
an
d
1–
po
si
tiv
e.
*D
O
R
w
as
7
an
d
13
m
on
th
s
in
th
e
tw
o
re
sp
on
de
rs
in
th
e
N
IV
O
3
gr
ou
p,
$
17
.4
in
th
e
on
e
re
sp
on
de
r
in
th
e
N
IV
O
1
+
IP
I3
gr
ou
p,
an
d
$
13
.8
m
on
th
s
in
th
e
re
sp
on
de
r
in
th
e
N
IV
O
3
+
IP
I1
gr
ou
p.
†
D
O
R
w
as
3.
0
an
d
$
26
.5
m
on
th
s
fo
r
th
e
tw
o
re
sp
on
de
rs
in
th
e
N
IV
O
3
gr
ou
p,
an
d
2.
5
m
on
th
s
in
th
e
on
e
re
sp
on
de
r
in
th
e
N
IV
O
3
+
IP
I1
gr
ou
p.
Th
e
m
ed
ia
n
D
O
R
w
as
4.
53
m
on
th
s
(9
5%
C
I,
2.
76
m
on
th
s
to
no
t
es
tim
ab
le
)
in
th
e
fo
ur
re
sp
on
de
rs
in
th
e
N
IV
O
1
+
IP
I3
gr
ou
p.
‡
P
at
ie
nt
s
w
ith
a
be
st
ob
je
ct
iv
e
re
sp
on
se
of
co
m
pl
et
e
re
sp
on
se
,
pa
rt
ia
lr
es
po
ns
e,
or
st
ab
le
di
se
as
e.
6 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Janjigian et al
Downloaded from ascopubs.org by University of Glasgow Library on August 17, 2018 from 130.209.115.202
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
With emerging data highlighting the importance of MSI as
a predictive biomarker of response to immune checkpoint
inhibitors,27,28 our exploratory analysis revealed that responses
were observed in patients with both MSI-H and non–MSI-H
tumors. The ORR seemed numerically higher in the MSI-H
subgroup; however, because of the small sample size, these
data are only hypothesis generating, and research in larger patient
subsets is needed to conﬁrm these ﬁndings.
This study adds to the current body of evidence supporting
the role of immune checkpoint inhibitors for the treatment
of patients with advanced esophagogastric cancers.9,10,12
Limitations of this phase I/II study include the absence of
a standard-of-care comparator and that the study was not
designed for formal comparisons across treatment groups. In
addition, identiﬁcation of potential biomarkers of response was
limited by the small sample size. Ongoing studies may identify
biomarker-deﬁned subgroups of patients likely to gain greater
beneﬁt from nivolumab-based therapy. Thus, the optimal
approach of when (earlier v later lines of therapy) and how
(alone or in combination) to incorporate nivolumab and
nivolumab plus ipilimumab into clinical practice is yet to be
determined.
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Fig 2. Kaplan-Meier curves of (A) investigator-
assessed progression-free survival (PFS) and
(B) overall survival (OS) in all enrolled patients by
treatment group: nivolumab 3 mg/kg (NIVO3),
nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
(NIVO1 + IPI3), and NIVO3 plus ipilimumab
1 mg/kg (NIVO3 + IPI1). Hash marks indicate
censored observations.
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In summary, our ﬁndings suggest that nivolumab and nivolumab
plus ipilimumab represent a potential therapeutic approach for pa-
tients with advanced esophagogastric cancer. Ongoing phase III studies
are investigating nivolumab in the adjuvant setting (NCT02743494)
and NIVO1 + IPI3 in the ﬁrst-line setting (NCT02872116) in patients
with esophagogastric cancer.
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Appendix
Supplementary Study Design
The criteria for discontinuation of treatment included the following treatment-related adverse events: grade 2 uveitis, grade 3
nonskin events lasting $ 7 days, grade 3 laboratory abnormalities of thrombocytopenia or liver function, all grade 4 events, and
laboratory abnormalities, except for asymptomatic amylase or lipase elevations. The criteria for dose delay (until resolution of the
treatment-related adverse event to grade 1 or lower) of nivolumab, ipilimumab, or both include the following treatment-related
adverse events: grade 2 or worse nonskin events (except for grade 2 fatigue or laboratory abnormalities, which do not require
a treatment delay), grade 3 skin events, and grade 3 laboratory abnormalities (except for asymptomatic amylase and lipase in-
creases). If the patient had normal AST, ALT, or total bilirubin concentrations at baseline, the dose would be delayed for grade 2 or
worse adverse events; if these laboratory parameters were grade 1 at baseline, the dose would be delayed for grade 3 or worse adverse
events.
Crossed over on progression (n = 10)
(n = 4)
(n = 6)
NIVO1 + IPI3
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Patients allocated to NIVO1 + IPI3
(n = 49)
Patients enrolled
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   Due to disease progression
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(n = 57; 97%)
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(n = 2; 3%)*
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(n = 9; 18%)†
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(n = 1; 2%)
(n = 0; 0%)
Fig A1. CONSORT diagram for study design and patient disposition. (*) Increased ALT/AST (n = 1 patient) and pneumonitis (n = 1 patient). (†) Increased ALT/AST (n = 3
patients); colitis (n = 2 patients); diarrhea (n = 2 patients); colitis, cystitis, and transaminitis (n = 1 patient); and diarrhea and hyperthyroidism (n = 1 patient). (‡) Acute renal
failure, autoimmune hepatitis, diarrhea, enteritis, increased ALT/AST, lymphocytic myocarditis, and pneumonitis (n = 1 patient each). AE, adverse event; IPI1, ipilimumab
1 mg/kg; IPI3, ipilimumab 3 mg/kg; NIVO1, nivolumab 1 mg/kg; NIVO3, nivolumab 3 mg/kg.
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Fig A2. Response characteristics in all responders by (A) investigator assessment and (B) blinded independent central review assessment. IPI1, ipilimumab 1 mg/kg;
IPI3, ipilimumab 3 mg/kg; MSI, microsatellite instability; MSI-H, microsatellite instability–high; NIVO1, nivolumab 1 mg/kg; NIVO3 nivolumab 3 mg/kg; PDL, programmed
death ligand; PD-L1+, programmed death-ligand 1–positive; PD-L12, programmed death-ligand 1–negative.
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Fig A3. Changes from baseline in target lesions over time per blinded independent central review assessment in patients treated with (A) nivolumab 3 mg/kg
monotherapy, (B) nivolumab 1 mg/kg plus ipilimumab 3 mg/kg, or (C) nivolumab 3 mg/kg plus ipilimumab 1 mg/kg. All data are based on the November 2016 database
cutoff, except for the blinded independent central review data for the nivolumab 3 mg/kg group, which are based on the March 2016 database cutoff. The + signs indicate
the occurrence of a new lesion, closed circles indicate off treatment, open squares represent percentage changes from baseline truncated at 100%, and red triangles
indicate investigator-assessed conﬁrmed complete or partial responses.
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Fig A4. Waterfall plot showingmaximum percentage change from baseline in size of tumors in patients treatedwith nivolumab 3mg/kg (NIVO3), nivolumab 1mg/kg plus
ipilimumab 3 mg/kg (NIVO1 + IPI3), and NIVO3 plus ipilimumab 1 mg/kg (NIVO3 + IPI1) per blinded independent central review. All data are based on the November 2016
database cutoff, except for the blinded independent central review data for the NIVO3 group, which are based on the March 2016 database cutoff. Patients with 0% best
reduction in target lesion are not shown on the plot (NIVO1 + IPI3; n = 1). (*) Indicates patients with a conﬁrmed response. Bars representing patients with a percentage
change in tumor burden that exceeded 100% have been truncated.
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Fig A5. Kaplan-Meier curves of progression-free survival (PFS) in patients treatedwith nivolumab 3mg/kg (NIVO3), nivolumab 1mg/kg plus ipilimumab 3mg/kg (NIVO1 +
IPI3), and NIVO3 plus ipilimumab 1 mg/kg (NIVO3 + IPI1) per blinded independent central review. All data are based on the November 2016 database cutoff, except for the
blinded independent central review data for the NIVO3 group, which are based on the March 2016 database cutoff.
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Table A1. Best Overall Response per Blinded Independent Central Review by PD-L1 Status
Response
NIVO3 (n = 59) NIVO1 + IPI 3 (n = 49) NIVO3 + IPI1 (n = 52)
PD-L1+ (n = 16) PD-L12 (n = 26) PD-L1+ (n = 10) PD-L12 (n = 32) PD-L1+ (n = 13) PD-L12 (n = 30)
ORR, No. (%; 95% CI) 2 (13; 2 to 38) 1 (4; 0 to 20) 4 (40; 12 to 74) 6 (19; 7 to 36) 1 (8; 0 to 36) 0 (0; 0 to 12)
Complete response 0 0 1 (10) 0 0 0
Partial response 2 (13) 1 (4) 3 (30) 6 (19) 1 (8) 0
Stable disease 3 (19) 12 (46) 1 (10) 10 (31) 3 (23) 12 (40)
Progressive disease 8 (50) 10 (39) 4 (40) 12 (38) 9 (69) 12 (40)
Unable to determine 3 (19) 3 (12) 1 (10) 4 (13) 0 6 (20)
NOTE. All data are based on the November 2016 database cutoff, except for the blinded independent central review data for the NIVO3 group, which are based on the
March 2016 database cutoff. Data presented as No. (%) unless otherwise indicated.
Abbreviations: IPI1, ipilimumab 1 mg/kg; IPI3, ipilimumab 3 mg/kg; NIVO 1, nivolumab 1 mg/kg; NIVO3, nivolumab 3 mg/kg; ORR, objective response rate; PD-L1+,
programmed death-ligand 1–positive; PD-L12, programmed death ligand 1–negative.
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